{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:31:17Z","timestamp":1793338277979,"version":"4.5.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41401-026-01868-9","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:08:16Z","timestamp":1783555696000},"page":"3102-3118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting"],"prefix":"10.1038","volume":"47","author":[{"given":"Rong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-fen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20:7\u201324.","journal-title":"Nat Rev Immunol"},{"key":"1868_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.smim.2017.12.002","volume":"35","author":"C Qian","year":"2018","unstructured":"Qian C, Cao X. Dendritic cells in the regulation of immunity and inflammation. Semin Immunol. 2018;35:3\u201311.","journal-title":"Semin Immunol"},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"eadf4726","DOI":"10.1126\/sciimmunol.adf4726","volume":"10","author":"V Bhandarkar","year":"2025","unstructured":"Bhandarkar V, Dinter T, Spranger S. Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer. Sci Immunol. 2025;10:eadf4726.","journal-title":"Sci Immunol"},{"key":"1868_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcdb.2017.12.009","volume":"84","author":"C Macri","year":"2018","unstructured":"Macri C, Pang ES, Patton T, O\u2019Keeffe M. Dendritic cell subsets. Semin Cell Dev Biol. 2018;84:11\u201321.","journal-title":"Semin Cell Dev Biol"},{"key":"1868_CR5","doi-asserted-by":"crossref","unstructured":"Gerhard GM, Bill R, Messemaker M, Klein AM, Pittet MJ. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J Exp Med. 2021;218:e20200264.","DOI":"10.1084\/jem.20200264"},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12:557\u201369.","journal-title":"Nat Rev Immunol"},{"key":"1868_CR7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.immuni.2022.04.016","volume":"55","author":"BW MacNabb","year":"2022","unstructured":"MacNabb BW, Tumuluru S, Chen X, Godfrey J, Kasal DN, Yu J, et al. Dendritic cells can prime anti-tumor CD8+ T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55:982\u201397.e988.","journal-title":"Immunity"},{"key":"1868_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1182\/blood-2003-12-4302","volume":"104","author":"S Bhattacharyya","year":"2004","unstructured":"Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS Jr, Tisch R. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K\/Akt pathway and of IkappaB kinase activity. Blood. 2004;104:1100\u20139.","journal-title":"Blood"},{"key":"1868_CR9","first-page":"1860","volume":"63","author":"JJ Kobie","year":"2003","unstructured":"Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003;63:1860\u20134.","journal-title":"Cancer Res"},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1756-9966-31-3","volume":"31","author":"K Imai","year":"2012","unstructured":"Imai K, Minamiya Y, Koyota S, Ito M, Saito H, Sato Y, et al. Inhibition of dendritic cell migration by transforming growth factor-\u03b21 increases tumor-draining lymph node metastasis. J Exp Clin Cancer Res. 2012;31:3.","journal-title":"J Exp Clin Cancer Res"},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nm.2172","volume":"16","author":"DL Herber","year":"2010","unstructured":"Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. 2010;16:880\u20136.","journal-title":"Nat Med"},{"key":"1868_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19192-z","volume":"11","author":"T Oba","year":"2020","unstructured":"Oba T, Long MD, Keler T, Marsh HC, Minderman H, Abrams SI, et al. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s. Nat Commun. 2020;11:5415.","journal-title":"Nat Commun"},{"key":"1868_CR13","doi-asserted-by":"publisher","first-page":"e2500296","DOI":"10.1002\/advs.202500296","volume":"12","author":"L Gehrcken","year":"2025","unstructured":"Gehrcken L, Deben C, Smits E, Van Audenaerde JRM. STING agonists and how to reach their full potential in cancer immunotherapy. Adv Sci (Weinh). 2025;12:e2500296.","journal-title":"Adv Sci (Weinh)"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","volume":"11","author":"A Ribas","year":"2021","unstructured":"Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma. Cancer Discov. 2021;11:2998\u20133007.","journal-title":"Cancer Discov"},{"key":"1868_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41551-025-01343-6","volume":"9","author":"J Wang","year":"2025","unstructured":"Wang J, Zhang Y, Jia Y, Xing H, Xu F, Xia B, et al. Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection. Nat Biomed Eng. 2025;9:201\u201314.","journal-title":"Nat Biomed Eng"},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-1-0716-4542-0_4","volume":"2926","author":"HM Maeng","year":"2025","unstructured":"Maeng HM, Olkhanud PB, Black M, Highfill SL, Stroncek DF, Berzofsky JA. Dendritic cell cancer vaccines: a focused review. Methods Mol Biol. 2025;2926:51\u201356.","journal-title":"Methods Mol Biol"},{"key":"1868_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","volume":"187","author":"Y Shapir Itai","year":"2024","unstructured":"Shapir Itai Y, Barboy O, Salomon R, Bercovich A, Xie K, Winter E, et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell. 2024;187:375\u201389.e318.","journal-title":"Cell"},{"key":"1868_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","volume":"31","author":"M Merad","year":"2013","unstructured":"Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563\u2013604.","journal-title":"Annu Rev Immunol"},{"key":"1868_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41568-024-00787-3","volume":"25","author":"CY Moon","year":"2025","unstructured":"Moon CY, Belabed M, Park MD, Mattiuz R, Puleston D, Merad M. Dendritic cell maturation in cancer. Nat Rev Cancer. 2025;25:225\u201348.","journal-title":"Nat Rev Cancer"},{"key":"1868_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","volume":"179","author":"CC Brown","year":"2019","unstructured":"Brown CC, Gudjonson H, Pritykin Y, Deep D, Lavall\u00e9e VP, Mendoza A, et al. Transcriptional basis of mouse and human dendritic cell heterogeneity. Cell. 2019;179:846\u201363.e824.","journal-title":"Cell"},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.20091627","volume":"207","author":"BT Edelson","year":"2010","unstructured":"Edelson BT, Kc W, Juang R, Kohyama M, Benoit LA, Klekotka PA, et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med. 2010;207:823\u201336.","journal-title":"J Exp Med"},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4:784\u201392.","journal-title":"Trends Cancer"},{"key":"1868_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2019.00009","volume":"10","author":"JC Cancel","year":"2019","unstructured":"Cancel JC, Crozat K, Dalod M, Mattiuz R. Are conventional type 1 dendritic cells critical for protective antitumor immunity and how? Front Immunol. 2019;10:9.","journal-title":"Front Immunol"},{"key":"1868_CR24","doi-asserted-by":"crossref","unstructured":"Rodriguez LIL, Amadio R, Piperno GM, Benvenuti F. Tissue-specific properties of type 1 dendritic cells in lung cancer: implications for immunotherapy. J Immunother Cancer. 2025;13:e010547.","DOI":"10.1136\/jitc-2024-010547"},{"key":"1868_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1146\/annurev-immunol-090122-041105","volume":"42","author":"NM Adams","year":"2024","unstructured":"Adams NM, Das A, Yun TJ, Reizis B. Ontogeny and function of plasmacytoid dendritic cells. Annu Rev Immunol. 2024;42:347\u201373.","journal-title":"Annu Rev Immunol"},{"key":"1868_CR26","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.4049\/jimmunol.2001347","volume":"206","author":"S Mansouri","year":"2021","unstructured":"Mansouri S, Katikaneni DS, Gogoi H, Jin L. Monocyte-derived dendritic cells (moDCs) differentiate into Bcl6+ mature moDCs to promote cyclic di-GMP vaccine adjuvant-induced memory THcells in the lung. J Immunol. 2021;206:2233\u201345.","journal-title":"J Immunol"},{"key":"1868_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1061031","volume":"13","author":"Y Liang","year":"2022","unstructured":"Liang Y, Wang H, Gonzales C, Thiriot J, Sunyakumthorn P, Melby PC, et al. CCR7\/dendritic cell axis mediates early bacterial dissemination in Orientia tsutsugamushi-infected mice. Front Immunol. 2022;13:1061031.","journal-title":"Front Immunol"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.immuni.2025.11.020","volume":"59","author":"B Zitti","year":"2026","unstructured":"Zitti B, Duval F, Wirapati P, Hicham M, Xie Y, Oh J, et al. Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. Immunity. 2026;59:161\u201376.e112.","journal-title":"Immunity"},{"key":"1868_CR29","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.1016\/j.cell.2021.07.015","volume":"184","author":"M Di Pilato","year":"2021","unstructured":"Di Pilato M, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184:4512\u201330.e4522.","journal-title":"Cell"},{"key":"1868_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44787-1","volume":"15","author":"CYC Lee","year":"2024","unstructured":"Lee CYC, Kennedy BC, Richoz N, Dean I, Tuong ZK, Gaspal F, et al. Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity. Nat Commun. 2024;15:682.","journal-title":"Nat Commun"},{"key":"1868_CR31","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","volume":"41","author":"P Meiser","year":"2023","unstructured":"Meiser P, Knolle MA, Hirschberger A, de Almeida GP, Bayerl F, Lacher S, et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell. 2023;41:1498\u2013515.e1410.","journal-title":"Cancer Cell"},{"key":"1868_CR32","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"10726","DOI":"10.1073\/pnas.1809925115","volume":"115","author":"CG Brise\u00f1o","year":"2018","unstructured":"Brise\u00f1o CG, Satpathy AT, Davidson JTT, Ferris ST, Durai V, Bagadia P, et al. Notch2-dependent DC2s mediate splenic germinal center responses. Proc Natl Acad Sci USA. 2018;115:10726\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1868_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.immuni.2015.04.017","volume":"42","author":"R Tussiwand","year":"2015","unstructured":"Tussiwand R, Everts B, Grajales-Reyes GE, Kretzer NM, Iwata A, Bagaitkar J, et al. Klf4 expression in conventional dendritic cells is required for T helper 2 cell responses. Immunity. 2015;42:916\u201328.","journal-title":"Immunity"},{"key":"1868_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4132","volume":"8","author":"PF Rodrigues","year":"2023","unstructured":"Rodrigues PF, Kouklas A, Cvijetic G, Bouladoux N, Mitrovic M, Desai JV, et al. pDC-like cells are pre-DC2 and require KLF4 to control homeostatic CD4 T cells. Sci Immunol. 2023;8:eadd4132.","journal-title":"Sci Immunol"},{"key":"1868_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41590-024-01745-9","volume":"25","author":"CM Minutti","year":"2024","unstructured":"Minutti CM, Piot C, Pereira da Costa M, Chakravarty P, Rogers N, Huerga Encabo H, et al. Distinct ontogenetic lineages dictate cDC2 heterogeneity. Nat Immunol. 2024;25:448\u201361.","journal-title":"Nat Immunol"},{"key":"1868_CR37","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.immuni.2024.05.007","volume":"57","author":"PF Rodrigues","year":"2024","unstructured":"Rodrigues PF, Trsan T, Cvijetic G, Khantakova D, Panda SK, Liu Z, et al. Progenitors of distinct lineages shape the diversity of mature type 2 conventional dendritic cells. Immunity. 2024;57:1567\u201385.e1565.","journal-title":"Immunity"},{"key":"1868_CR38","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-24-3595","volume":"85","author":"T Ma","year":"2025","unstructured":"Ma T, Chu X, Wang J, Li X, Zhang Y, Tong D, et al. Pan-cancer analyses refine the single-cell portrait of tumor-infiltrating dendritic cells. Cancer Res. 2025;85:3596\u2013613.","journal-title":"Cancer Res"},{"key":"1868_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792\u2013809.e723.","journal-title":"Cell"},{"key":"1868_CR40","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","volume":"55","author":"E Duong","year":"2022","unstructured":"Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, et al. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 2022;55:308\u201323.e309.","journal-title":"Immunity"},{"key":"1868_CR41","doi-asserted-by":"crossref","unstructured":"Ghislat G, Cheema AS, Baudoin E, Verthuy C, Ballester PJ, Crozat K, et al. NF-\u03baB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity. Sci Immunol. 2021;6:eabg3570.","DOI":"10.1126\/sciimmunol.abg3570"},{"key":"1868_CR42","doi-asserted-by":"crossref","unstructured":"Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 2017;356:eaah4573.","DOI":"10.1126\/science.aah4573"},{"key":"1868_CR43","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1016\/j.celrep.2019.11.042","volume":"29","author":"R Leylek","year":"2019","unstructured":"Leylek R, Alc\u00e1ntara-Hern\u00e1ndez M, Lanzar Z, L\u00fcdtke A, Perez OA, Reizis B, et al. Integrated cross-species analysis identifies a conserved transitional dendritic cell population. Cell Rep. 2019;29:3736\u201350.e3738.","journal-title":"Cell Rep"},{"key":"1868_CR44","doi-asserted-by":"crossref","unstructured":"See P, Dutertre CA, Chen J, G\u00fcnther P, McGovern N, Irac SE, et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science. 2017;356:eaag3009.","DOI":"10.1126\/science.aag3009"},{"key":"1868_CR45","doi-asserted-by":"publisher","first-page":"e1012351","DOI":"10.1371\/journal.ppat.1012351","volume":"20","author":"FA Warner van Dijk","year":"2024","unstructured":"Warner van Dijk FA, Tong O, O\u2019Neil TR, Bertram KM, Hu K, Baharlou H, et al. Characterising plasmacytoid and myeloid AXL+ SIGLEC-6+ dendritic cell functions and their interactions with HIV. PLoS Pathog. 2024;20:e1012351.","journal-title":"PLoS Pathog"},{"key":"1868_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1189\/jlb.1HI0714-351R","volume":"97","author":"V Bigley","year":"2015","unstructured":"Bigley V, McGovern N, Milne P, Dickinson R, Pagan S, Cookson S, et al. Langerin-expressing dendritic cells in human tissues are related to CD1c+ dendritic cells and distinct from Langerhans cells and CD141high XCR1+ dendritic cells. J Leukoc Biol. 2015;97:627\u201334.","journal-title":"J Leukoc Biol"},{"key":"1868_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J, et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature. 2020;580:257\u201362.","journal-title":"Nature"},{"key":"1868_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1199","volume":"13","author":"J Li","year":"2023","unstructured":"Li J, Zhou J, Huang H, Jiang J, Zhang T, Ni C. Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumour microenvironment and immunotherapy target. Clin Transl Med. 2023;13:e1199.","journal-title":"Clin Transl Med"},{"key":"1868_CR49","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","volume":"42","author":"S You","year":"2024","unstructured":"You S, Li S, Zeng L, Song J, Li Z, Li W, et al. Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity. Cancer Cell. 2024;42:1415\u201333.e1412.","journal-title":"Cancer Cell"},{"key":"1868_CR50","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi4191","volume":"9","author":"MP Plebanek","year":"2024","unstructured":"Plebanek MP, Xue Y, Nguyen YV, DeVito NC, Wang X, Holtzhausen A, et al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci Immunol. 2024;9:eadi4191.","journal-title":"Sci Immunol"},{"key":"1868_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62878-5","volume":"16","author":"J Yang","year":"2025","unstructured":"Yang J, Wang C, Fu D, Ho LL, Galani K, Chen L, et al. Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma. Nat Commun. 2025;16:8151.","journal-title":"Nat Commun"},{"key":"1868_CR52","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21:298\u2013312.","journal-title":"Nat Rev Cancer"},{"key":"1868_CR53","doi-asserted-by":"crossref","unstructured":"Xiao Z, Wang J, Yang J, Guo F, Zhang L, Zhang L. Dendritic cells instruct T cell anti-tumor immunity and immunotherapy response. Innov Med. 2025;3:100128.","DOI":"10.59717\/j.xinn-med.2025.100128"},{"key":"1868_CR54","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood.V95.11.3473","volume":"95","author":"V Russo","year":"2000","unstructured":"Russo V, Zhou D, Sartirana C, Rovere P, Villa A, Rossini S, et al. Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. Blood. 2000;95:3473\u20137.","journal-title":"Blood"},{"key":"1868_CR55","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.4049\/jimmunol.172.4.2126","volume":"172","author":"F Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I\/peptide complexes to dendritic cells. J Immunol. 2004;172:2126\u201336.","journal-title":"J Immunol"},{"key":"1868_CR56","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.4049\/jimmunol.177.9.6018","volume":"177","author":"BP Dolan","year":"2006","unstructured":"Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. J Immunol. 2006;177:6018\u201324.","journal-title":"J Immunol"},{"key":"1868_CR57","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature09863","volume":"471","author":"LM Wakim","year":"2011","unstructured":"Wakim LM, Bevan MJ. Cross-dressed dendritic cells drive memory CD8+ T-cell activation after viral infection. Nature. 2011;471:629\u201332.","journal-title":"Nature"},{"key":"1868_CR58","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1172\/JCI84577","volume":"126","author":"Q Liu","year":"2016","unstructured":"Liu Q, Rojas-Canales DM, Divito SJ, Shufesky WJ, Stolz DB, Erdos G, et al. Donor dendritic cell-derived exosomes promote allograft-targeting immune response. J Clin Invest. 2016;126:2805\u201320.","journal-title":"J Clin Invest"},{"key":"1868_CR59","doi-asserted-by":"crossref","unstructured":"Marino J, Babiker-Mohamed MH, Crosby-Bertorini P, Paster JT, LeGuern C, Germana S, et al. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. Sci Immunol. 2016;1:aaf8759.","DOI":"10.1126\/sciimmunol.aaf8759"},{"key":"1868_CR60","doi-asserted-by":"publisher","first-page":"12716","DOI":"10.1073\/pnas.1203468109","volume":"109","author":"L Li","year":"2012","unstructured":"Li L, Kim S, Herndon JM, Goedegebuure P, Belt BA, Satpathy AT, et al. Cross-dressed CD8\u03b1+\/CD103+ dendritic cells prime CD8+ T cells following vaccination. Proc Natl Acad Sci USA. 2012;109:12716\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1868_CR61","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/2326-6066.CIR-20-0248","volume":"8","author":"A Das Mohapatra","year":"2020","unstructured":"Das Mohapatra A, Tirrell I, B\u00e9n\u00e9chet AP, Pattnayak S, Khanna KM, Srivastava PK. Cross-dressing of CD8\u03b1+ dendritic cells with antigens from live mouse tumor cells is a major mechanism of cross-priming. Cancer Immunol Res. 2020;8:1287\u201399.","journal-title":"Cancer Immunol Res"},{"key":"1868_CR62","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.ccell.2020.05.002","volume":"37","author":"MK Ruhland","year":"2020","unstructured":"Ruhland MK, Roberts EW, Cai E, Mujal AM, Marchuk K, Beppler C, et al. Visualizing synaptic transfer of tumor antigens among dendritic cells. Cancer Cell. 2020;37:786\u201399.e785.","journal-title":"Cancer Cell"},{"key":"1868_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1341685","volume":"11","author":"IA Ishina","year":"2023","unstructured":"Ishina IA, Kurbatskaia IN, Mamedov AE, Shramova EI, Deyev SM, Nurbaeva KS, et al. Genetically engineered CD80-pMHC-harboring extracellular vesicles for antigen-specific CD4+ T-cell engagement. Front Bioeng Biotechnol. 2023;11:1341685.","journal-title":"Front Bioeng Biotechnol"},{"key":"1868_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq4060","volume":"17","author":"Y Mohammadzadeh","year":"2025","unstructured":"Mohammadzadeh Y, Gligorovski V, Egorova O, Casagrande Raffi G, van der Schans JJ, Ghasemi A, et al. Coordinate tumor-antigen uptake and dendritic cell activation by chimeric antigen receptors. Sci Transl Med. 2025;17:eadq4060.","journal-title":"Sci Transl Med"},{"key":"1868_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64172-w","volume":"16","author":"A Ghasemi","year":"2025","unstructured":"Ghasemi A, Martinez-Usatorre A, Liu Y, Demagny H, Li L, Mohammadzadeh Y, et al. Dendritic cell progenitors engineered to express extracellular-vesicle-internalizing receptors enhance cancer immunotherapy in mouse models. Nat Commun. 2025;16:9148.","journal-title":"Nat Commun"},{"key":"1868_CR66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature. 2016;537:417\u201321.","journal-title":"Nature"},{"key":"1868_CR67","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1084\/jem.20180684","volume":"215","author":"J Brummelman","year":"2018","unstructured":"Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, et al. High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. J Exp Med. 2018;215:2520\u201335.","journal-title":"J Exp Med"},{"key":"1868_CR68","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"JC Beltra","year":"2020","unstructured":"Beltra JC, Manne S, Abdel-Hakeem MS, Kurachi M, Giles JR, Chen Z, et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825\u201341.e828.","journal-title":"Immunity"},{"key":"1868_CR69","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41590-024-01896-9","volume":"25","author":"CC Zebley","year":"2024","unstructured":"Zebley CC, Zehn D, Gottschalk S, Chi H. T cell dysfunction and therapeutic intervention in cancer. Nat Immunol. 2024;25:1344\u201354.","journal-title":"Nat Immunol"},{"key":"1868_CR70","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/s41590-025-02330-4","volume":"26","author":"R Li","year":"2025","unstructured":"Li R, Wei K, Sun Q, Xie B, Wei P, Xie T, et al. Analysis of the three-dimensional genome of exhausted CD8+ T cells reveals a critical role of IRF8 in their differentiation and functions in cancer. Nat Immunol. 2025;26:2280\u201395.","journal-title":"Nat Immunol"},{"key":"1868_CR71","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","volume":"56","author":"JR Giles","year":"2023","unstructured":"Giles JR, Globig AM, Kaech SM, Wherry EJ. CD8+ T cells in the cancer-immunity cycle. Immunity. 2023;56:2231\u201353.","journal-title":"Immunity"},{"key":"1868_CR72","doi-asserted-by":"crossref","unstructured":"Shakiba M, Zumbo P, Espinosa-Carrasco G, Menocal L, D\u00fcndar F, Carson SE, et al. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. J Exp Med. 2022;219:e20201966.","DOI":"10.1084\/jem.20201966"},{"key":"1868_CR73","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","volume":"56","author":"M Zagorulya","year":"2023","unstructured":"Zagorulya M, Yim L, Morgan DM, Edwards A, Torres-Mejia E, Momin N, et al. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Immunity. 2023;56:386\u2013405.e310.","journal-title":"Immunity"},{"key":"1868_CR74","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41577-024-01061-1","volume":"24","author":"MT Lotze","year":"2024","unstructured":"Lotze MT, Olejniczak SH, Skokos D. CD28 co-stimulation: novel insights and applications in cancer immunotherapy. Nat Rev Immunol. 2024;24:878\u201395.","journal-title":"Nat Rev Immunol"},{"key":"1868_CR75","doi-asserted-by":"crossref","unstructured":"Horton BL, D\u2019Souza AD, Zagorulya M, McCreery CV, Abhiraman GC, Picton L, et al. Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2. JCI Insight. 2023;8:e172728.","DOI":"10.1172\/jci.insight.172728"},{"key":"1868_CR76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","volume":"56","author":"N Prokhnevska","year":"2023","unstructured":"Prokhnevska N, Cardenas MA, Valanparambil RM, Sobierajska E, Barwick BG, Jansen C, et al. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity. 2023;56:107\u201324.e105.","journal-title":"Immunity"},{"key":"1868_CR77","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","volume":"54","author":"JM Schenkel","year":"2021","unstructured":"Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan SL, et al. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity. 2021;54:2338\u201353.e2336.","journal-title":"Immunity"},{"key":"1868_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg7836","volume":"6","author":"KA Connolly","year":"2021","unstructured":"Connolly KA, Kuchroo M, Venkat A, Khatun A, Wang J, William I, et al. A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response. Sci Immunol. 2021;6:eabg7836.","journal-title":"Sci Immunol"},{"key":"1868_CR79","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen CS, Prokhnevska N, Master VA, Sanda MG, Carlisle JW, Bilen MA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576:465\u201370.","journal-title":"Nature"},{"key":"1868_CR80","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.immuni.2022.03.006","volume":"55","author":"S D\u00e4hling","year":"2022","unstructured":"D\u00e4hling S, Mansilla AM, Kn\u00f6pper K, Grafen A, Utzschneider DT, Ugur M, et al. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. Immunity. 2022;55:656\u201370.e658.","journal-title":"Immunity"},{"key":"1868_CR81","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","volume":"29","author":"A Magen","year":"2023","unstructured":"Magen A, Hamon P, Fiaschi N, Soong BY, Park MD, Mattiuz R, et al. Intratumoral dendritic cell-CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat Med. 2023;29:1389\u201399.","journal-title":"Nat Med"},{"key":"1868_CR82","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26:638\u201352.","journal-title":"Cancer Cell"},{"key":"1868_CR83","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44:924\u201338.","journal-title":"Immunity"},{"key":"1868_CR84","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","volume":"92","author":"DIT Gabrilovich","year":"1998","unstructured":"Gabrilovich DIT, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150\u201366.","journal-title":"Blood"},{"key":"1868_CR85","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/blood-2011-11-370130","volume":"119","author":"L van de Laar","year":"2012","unstructured":"van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood. 2012;119:3383\u201393.","journal-title":"Blood"},{"key":"1868_CR86","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1158\/1078-0432.CCR-19-1321","volume":"26","author":"CS Garris","year":"2020","unstructured":"Garris CS, Luke JJ. Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response. Clin Cancer Res. 2020;26:3901\u20137.","journal-title":"Clin Cancer Res"},{"key":"1868_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621812","volume":"16","author":"KJ Racacho","year":"2025","unstructured":"Racacho KJ, Shiau YP, Villa R, Mahri S, Tang M, Lin TY, et al. The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches. Front Immunol. 2025;16:1621812.","journal-title":"Front Immunol"},{"key":"1868_CR88","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12026-015-8700-y","volume":"63","author":"C Martin","year":"2015","unstructured":"Martin C, Espaillat MP, Santiago-Schwarz F. IL-10 restricts dendritic cell (DC) growth at the monocyte-to-monocyte-derived DC interface by disrupting anti-apoptotic and cytoprotective autophagic molecular machinery. Immunol Res. 2015;63:131\u201343.","journal-title":"Immunol Res"},{"key":"1868_CR89","doi-asserted-by":"crossref","unstructured":"Brandum EP, J\u00f8rgensen AS, Rosenkilde MM, Hjort\u00f8 GM. Dendritic cells and CCR7 expression: an important factor for autoimmune diseases, chronic inflammation, and cancer. Int J Mol Sci. 2021;22:8340.","DOI":"10.3390\/ijms22158340"},{"key":"1868_CR90","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00262-008-0487-4","volume":"57","author":"P Stoitzner","year":"2008","unstructured":"Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, et al. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother. 2008;57:1665\u201373.","journal-title":"Cancer Immunol Immunother"},{"key":"1868_CR91","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri1457","volume":"4","author":"AL Mellor","year":"2004","unstructured":"Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1868_CR92","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31:711\u201323.e714.","journal-title":"Cancer Cell"},{"key":"1868_CR93","doi-asserted-by":"crossref","unstructured":"Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12:eaav7431.","DOI":"10.1126\/scitranslmed.aav7431"},{"key":"1868_CR94","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1158\/1078-0432.CCR-23-3477","volume":"30","author":"S Saito","year":"2024","unstructured":"Saito S, Kono M, Nguyen HCB, Egloff AM, Messier C, Lizotte P, et al. Targeting dendritic cell dysfunction to circumvent anti-PD1 resistance in head and neck cancer. Clin Cancer Res. 2024;30:1934\u201344.","journal-title":"Clin Cancer Res"},{"key":"1868_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner S, Cords L, Kasser S, Freiberger SN, Kreutzer S, Toussaint NC, et al. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat Commun. 2023;14:5154.","journal-title":"Nat Commun"},{"key":"1868_CR96","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022;28:1848\u201359.","journal-title":"Nat Med"},{"key":"1868_CR97","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26:1878\u201387.","journal-title":"Nat Med"},{"key":"1868_CR98","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28:1872\u201382.","journal-title":"Nat Med"},{"key":"1868_CR99","doi-asserted-by":"crossref","unstructured":"Gorline L, Do Carmo FL, Bourdely P, Born\u00e8res J, Vaudiau N, Semervil A, et al. Intratumoral delivery of FLT3L with CXCR3\/CCR5 ligands promotes XCR1+ cDC1 infiltration and activates anti-tumor immunity. Nat Commun. 2025; 17:1258.","DOI":"10.1038\/s41467-025-68018-3"},{"key":"1868_CR100","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3389\/fimmu.2018.01042","volume":"9","author":"R Iwabuchi","year":"2018","unstructured":"Iwabuchi R, Ikeno S, Kobayashi-Ishihara M, Takeyama H, Ato M, Tsunetsugu-Yokota Y, et al. Introduction of Human Flt3-L and GM-CSF into humanized mice enhances the reconstitution and maturation of myeloid dendritic cells and the development of Foxp3+CD4+ T cells. Front Immunol. 2018;9:1042.","journal-title":"Front Immunol"},{"key":"1868_CR101","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1084\/jem.20030323","volume":"198","author":"H Karsunky","year":"2003","unstructured":"Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003;198:305\u201313.","journal-title":"J Exp Med"},{"key":"1868_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1058963","volume":"13","author":"SM Lellahi","year":"2022","unstructured":"Lellahi SM, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, et al. GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Front Immunol. 2022;13:1058963.","journal-title":"Front Immunol"},{"key":"1868_CR103","doi-asserted-by":"crossref","unstructured":"Lam B, Kung YJ, Lin J, Tseng SH, Tu HF, Huang C, et al. In situ vaccination via tissue-targeted cDC1 expansion enhances the immunogenicity of chemoradiation and immunotherapy. J Clin Invest. 2024;134:e171621.","DOI":"10.1172\/JCI171621"},{"key":"1868_CR104","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-020-00143-y","volume":"1","author":"N Bhardwaj","year":"2020","unstructured":"Bhardwaj N, Friedlander PA, Pavlick AC, Ernstoff MS, Gastman BR, Hanks BA, et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer. 2020;1:1204\u201317.","journal-title":"Nat Cancer"},{"key":"1868_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649891","volume":"16","author":"Q Zheng","year":"2025","unstructured":"Zheng Q, Zhang J, Sui H, Sun Y, Lv N, Liu L, et al. FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8+ T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy. Front Immunol. 2025;16:1649891.","journal-title":"Front Immunol"},{"key":"1868_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46685-y","volume":"15","author":"L L\u00f3pez","year":"2024","unstructured":"L\u00f3pez L, Morosi LG, La Terza F, Bourdely P, Rospo G, Amadio R, et al. Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors. Nat Commun. 2024;15:2280.","journal-title":"Nat Commun"},{"key":"1868_CR107","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13:81.","journal-title":"J Hematol Oncol"},{"key":"1868_CR108","doi-asserted-by":"publisher","first-page":"102172","DOI":"10.1016\/j.cbpa.2022.102172","volume":"70","author":"A Kaur","year":"2022","unstructured":"Kaur A, Baldwin J, Brar D, Salunke DB, Petrovsky N. Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics. Curr Opin Chem Biol. 2022;70:102172.","journal-title":"Curr Opin Chem Biol"},{"key":"1868_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19:136.","journal-title":"Mol Cancer"},{"key":"1868_CR110","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.immuni.2011.05.006","volume":"34","author":"T Kawai","year":"2011","unstructured":"Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637\u201350.","journal-title":"Immunity"},{"key":"1868_CR111","doi-asserted-by":"publisher","first-page":"10685","DOI":"10.2147\/IJN.S477320","volume":"19","author":"ARS Ribeiro","year":"2024","unstructured":"Ribeiro ARS, Neuper T, Horejs-Hoeck J. The role of STING-mediated activation of dendritic cells in cancer immunotherapy. Int J Nanomed. 2024;19:10685\u201397.","journal-title":"Int J Nanomed"},{"key":"1868_CR112","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180:1044\u201366.","journal-title":"Cell"},{"key":"1868_CR113","doi-asserted-by":"crossref","unstructured":"Koster BD, L\u00f3pez Gonz\u00e1lez M, van den Hout MF, Turksma AW, Sluijter BJ, Molenkamp BG, et al. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A+CD141+ cDC1 and CD14+ antigen-presenting cell recruitment. J Immunother Cancer. 2021;9:e001962.","DOI":"10.1136\/jitc-2020-001962"},{"key":"1868_CR114","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","volume":"2","author":"SE Ackerman","year":"2021","unstructured":"Ackerman SE, Pearson CI, Gregorio JD, Gonzalez JC, Kenkel JA, Hartmann FJ, et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat Cancer. 2021;2:18\u201333.","journal-title":"Nat Cancer"},{"key":"1868_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207486","volume":"34","author":"J Yan","year":"2022","unstructured":"Yan J, Zhang Y, Du S, Hou X, Li W, Zeng C, et al. Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Adv Mater. 2022;34:e2207486.","journal-title":"Adv Mater"},{"key":"1868_CR116","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47\u201358.","journal-title":"Annu Rev Med"},{"key":"1868_CR117","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","volume":"19","author":"TNJ Bullock","year":"2022","unstructured":"Bullock TNJ. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol Immunol. 2022;19:14\u201322.","journal-title":"Cell Mol Immunol"},{"key":"1868_CR118","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","volume":"25","author":"JL Van Laethem","year":"2024","unstructured":"Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol. 2024;25:853\u201364.","journal-title":"Lancet Oncol"},{"key":"1868_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66092-1","volume":"16","author":"S Kucukcelebi","year":"2025","unstructured":"Kucukcelebi S, van \u2018t Land FR, van der Burg SH, Eskens F, Homs MYV, Willemsen M, et al. REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer. Nat Commun. 2025;16:10609.","journal-title":"Nat Commun"},{"key":"1868_CR120","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","volume":"30","author":"SA Weiss","year":"2024","unstructured":"Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero M, Couselo EM, Rodr\u00edguez-Abreu D, et al. A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Clin Cancer Res. 2024;30:74\u201381.","journal-title":"Clin Cancer Res"},{"key":"1868_CR121","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, Maurer DM, O\u2019Hara MH, O\u2019Reilly EM, Wolff RA, Wainberg ZA, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28:1167\u201377.","journal-title":"Nat Med"},{"key":"1868_CR122","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clin Cancer Res. 2021;27:4574\u201386.","journal-title":"Clin Cancer Res"},{"key":"1868_CR123","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1158\/1535-7163.MCT-24-0999","volume":"24","author":"LM Wang","year":"2025","unstructured":"Wang LM, Yang C, Sun X, Tian Y, Zhang J, Wang X, et al. SHR-2005, an Fc\u03b3R-dependent CD40 agonistic antibody with potent antitumor activities and favorable safety profile. Mol Cancer Ther. 2025;24:1671\u201384.","journal-title":"Mol Cancer Ther"},{"key":"1868_CR124","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/2326-6066.CIR-21-0553","volume":"10","author":"N Rigamonti","year":"2022","unstructured":"Rigamonti N, Veitonm\u00e4ki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, et al. A multispecific anti-CD40 DARP in construct induces tumor-selective CD40 activation and tumor regression. Cancer Immunol Res. 2022;10:626\u201340.","journal-title":"Cancer Immunol Res"},{"key":"1868_CR125","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489\u201396.","journal-title":"Nat Mater"},{"key":"1868_CR126","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","volume":"15","author":"W Wang","year":"2020","unstructured":"Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020;15:406\u201316.","journal-title":"Nat Nanotechnol"},{"key":"1868_CR127","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","volume":"17","author":"C Liu","year":"2022","unstructured":"Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022;17:531\u201340.","journal-title":"Nat Nanotechnol"},{"key":"1868_CR128","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","volume":"3","author":"R Salomon","year":"2022","unstructured":"Salomon R, Rotem H, Katzenelenbogen Y, Weiner A, Cohen Saban N, Feferman T, et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat Cancer. 2022;3:287\u2013302.","journal-title":"Nat Cancer"},{"key":"1868_CR129","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","volume":"14","author":"J Conniot","year":"2019","unstructured":"Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos AI, et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019;14:891\u2013901.","journal-title":"Nat Nanotechnol"},{"key":"1868_CR130","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41551-024-01208-4","volume":"9","author":"D Yin","year":"2025","unstructured":"Yin D, Zhong Y, Ling S, Lu S, Wang X, Jiang Z, et al. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat Biomed Eng. 2025;9:185\u2013200.","journal-title":"Nat Biomed Eng"},{"key":"1868_CR131","doi-asserted-by":"publisher","first-page":"18590","DOI":"10.1021\/acsami.2c20846","volume":"15","author":"L Zheng","year":"2023","unstructured":"Zheng L, Wu H, Wen N, Zhang Y, Wang Z, Peng X, et al. Aptamer-functionalized nanovaccines: targeting in vivo DC subsets for enhanced antitumor immunity. ACS Appl Mater Interfaces. 2023;15:18590\u20137.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1868_CR132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2301606120","volume":"120","author":"E Ben-Akiva","year":"2023","unstructured":"Ben-Akiva E, Karlsson J, Hemmati S, Yu H, Tzeng SY, Pardoll DM, et al. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. Proc Natl Acad Sci USA. 2023;120:e2301606120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1868_CR133","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","volume":"28","author":"JL Hu","year":"2022","unstructured":"Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, et al. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clin Cancer Res. 2022;28:689\u201396.","journal-title":"Clin Cancer Res"},{"key":"1868_CR134","doi-asserted-by":"crossref","unstructured":"Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, et al. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021;9:e003675.","DOI":"10.1136\/jitc-2021-003675"},{"key":"1868_CR135","volume":"4","author":"IF Parney","year":"2022","unstructured":"Parney IF, Anderson SK, Gustafson MP, Steinmetz S, Peterson TE, Kroneman TN, et al. Phase I trial of adjuvant mature autologous dendritic cell\/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma. Neurooncol Adv. 2022;4:vdac089.","journal-title":"Neurooncol Adv"},{"key":"1868_CR136","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023;9:112\u201321.","journal-title":"JAMA Oncol"},{"key":"1868_CR137","first-page":"2217","volume":"38","author":"R Yanagisawa","year":"2018","unstructured":"Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, et al. WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study. Anticancer Res. 2018;38:2217\u201325.","journal-title":"Anticancer Res"},{"key":"1868_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571182","volume":"16","author":"K Oyama","year":"2025","unstructured":"Oyama K, Nakata K, Abe T, Hirotaka K, Fujimori N, Kiyotani K, et al. Neoantigen peptide-pulsed dendritic cell vaccine therapy after surgical treatment of pancreatic cancer: a retrospective study. Front Immunol. 2025;16:1571182.","journal-title":"Front Immunol"},{"key":"1868_CR139","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"1868_CR140","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, L\u00f6wer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222\u20136.","journal-title":"Nature"},{"key":"1868_CR141","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.omto.2020.06.019","volume":"18","author":"ASS Do","year":"2020","unstructured":"Do ASS, Amano T, Edwards LA, Zhang L, De Peralta-Venturina M, Yu JS. CD133 mRNA-loaded dendritic cell vaccination abrogates glioma stem cell propagation in humanized glioblastoma mouse model. Mol Ther Oncolytics. 2020;18:295\u2013303.","journal-title":"Mol Ther Oncolytics"},{"key":"1868_CR142","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s00262-020-02618-4","volume":"69","author":"Y Jansen","year":"2020","unstructured":"Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, et al. A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III\/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother. 2020;69:2589\u201398.","journal-title":"Cancer Immunol Immunother"},{"key":"1868_CR143","doi-asserted-by":"crossref","unstructured":"De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, et al. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer. 2020; 8:e000329.","DOI":"10.1136\/jitc-2019-000329"},{"key":"1868_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1111523","volume":"14","author":"W de Mey","year":"2023","unstructured":"de Mey W, Locy H, De Ridder K, De Schrijver P, Autaers D, Lakdimi A, et al. An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8+ T cells. Front Immunol. 2023;14:1111523.","journal-title":"Front Immunol"},{"key":"1868_CR145","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1172\/JCI31205","volume":"117","author":"E Gilboa","year":"2007","unstructured":"Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117:1195\u2013203.","journal-title":"J Clin Invest"},{"key":"1868_CR146","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74\u201395.","journal-title":"Cell Res"},{"key":"1868_CR147","first-page":"6451","volume":"61","author":"J Banchereau","year":"2001","unstructured":"Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451\u20138.","journal-title":"Cancer Res"},{"key":"1868_CR148","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","volume":"5","author":"A Ghasemi","year":"2024","unstructured":"Ghasemi A, Martinez-Usatorre A, Li L, Hicham M, Guichard A, Marcone R, et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat Cancer. 2024;5:240\u201361.","journal-title":"Nat Cancer"},{"key":"1868_CR149","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1158\/2326-6066.CIR-17-0112","volume":"5","author":"OJ Finn","year":"2017","unstructured":"Finn OJ. Human tumor antigens yesterday, today, and tomorrow. Cancer Immunol Res. 2017;5:347\u201354.","journal-title":"Cancer Immunol Res"},{"key":"1868_CR150","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"1868_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101516","volume":"5","author":"J Ingels","year":"2024","unstructured":"Ingels J, De Cock L, Stevens D, Mayer RL, Th\u00e9ry F, Sanchez GS, et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep Med. 2024;5:101516.","journal-title":"Cell Rep Med"},{"key":"1868_CR152","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49:1148\u201361.e1147.","journal-title":"Immunity"},{"key":"1868_CR153","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ccell.2024.05.025","volume":"42","author":"G Espinosa-Carrasco","year":"2024","unstructured":"Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell. 2024;42:1202\u201316.e1208.","journal-title":"Cancer Cell"},{"key":"1868_CR154","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1016\/j.cell.2024.10.016","volume":"187","author":"F Lin","year":"2024","unstructured":"Lin F, Yin S, Zhang Z, Yu Y, Fang H, Liang Z, et al. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell. 2024;187:7470\u201391.e7432.","journal-title":"Cell"},{"key":"1868_CR155","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35:473\u201388.e476.","journal-title":"Cancer Cell"},{"key":"1868_CR156","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","volume":"21","author":"J Lai","year":"2020","unstructured":"Lai J, Mardiana S, House IG, Sek K, Henderson MA, Giuffrida L, et al. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. Nat Immunol. 2020;21:914\u201326.","journal-title":"Nat Immunol"},{"key":"1868_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102307","volume":"6","author":"Z Xiao","year":"2025","unstructured":"Xiao Z, Wang J, He S, Wang L, Yang J, Li W, et al. Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. Cell Rep Med. 2025;6:102307.","journal-title":"Cell Rep Med"},{"key":"1868_CR158","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nri3865","volume":"15","author":"M Swiecki","year":"2015","unstructured":"Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol. 2015;15:471\u201385.","journal-title":"Nat Rev Immunol"},{"key":"1868_CR159","doi-asserted-by":"publisher","first-page":"749190","DOI":"10.3389\/fimmu.2021.749190","volume":"12","author":"B Zhou","year":"2021","unstructured":"Zhou B, Lawrence T, Liang Y. The role of plasmacytoid dendritic cells in cancers. Front Immunol. 2021;12:749190.","journal-title":"Front Immunol"},{"key":"1868_CR160","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4161\/onci.18801","volume":"1","author":"SI Labidi-Galy","year":"2012","unstructured":"Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology. 2012;1:380\u20132.","journal-title":"Oncoimmunology"},{"key":"1868_CR161","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ijc.28072","volume":"133","author":"V Sisirak","year":"2013","unstructured":"Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, et al. Breast cancer-derived transforming growth factor-\u03b2 and tumor necrosis factor-\u03b1 compromise interferon-\u03b1 production by tumor-associated plasmacytoid dendritic cells. Int J Cancer. 2013;133:771\u20138.","journal-title":"Int J Cancer"},{"key":"1868_CR162","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1084\/jem.20061660","volume":"204","author":"T Ito","year":"2007","unstructured":"Ito T, Yang M, Wang YH, Lande R, Gregorio J, Perng OA, et al. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007;204:105\u201315.","journal-title":"J Exp Med"},{"key":"1868_CR163","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cmet.2016.04.010","volume":"23","author":"TJ Yun","year":"2016","unstructured":"Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, et al. Indoleamine 2,3-dioxygenase-expressing aortic plasmacytoid dendritic cells protect against atherosclerosis by induction of regulatory T cells. Cell Metab. 2016;23:852\u201366.","journal-title":"Cell Metab"},{"key":"1868_CR164","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","volume":"51","author":"CA Dutertre","year":"2019","unstructured":"Dutertre CA, Becht E, Irac SE, Khalilnezhad A, Narang V, Khalilnezhad S, et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity. 2019;51:573\u201389.e578.","journal-title":"Immunity"},{"key":"1868_CR165","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.it.2023.10.005","volume":"44","author":"A Rigamonti","year":"2023","unstructured":"Rigamonti A, Villar J, Segura E. Monocyte differentiation within tissues: a renewed outlook. Trends Immunol. 2023;44:999\u20131013.","journal-title":"Trends Immunol"},{"key":"1868_CR166","doi-asserted-by":"publisher","DOI":"10.1111\/imr.70075","volume":"336","author":"E Segura","year":"2025","unstructured":"Segura E. Monocyte-derived dendritic cells: an updated view on an old concept. Immunol Rev. 2025;336:e70075.","journal-title":"Immunol Rev"},{"key":"1868_CR167","doi-asserted-by":"crossref","unstructured":"Tadepalli S, Clements DR, Raquer-McKay HM, L\u00fcdtke A, Saravanan S, Seong D, et al. CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy. J Exp Med. 2025;222:e20231717.","DOI":"10.1084\/jem.20231717"},{"key":"1868_CR168","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood-2008-11-191197","volume":"114","author":"DJ Chung","year":"2009","unstructured":"Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood. 2009;114:555\u201363.","journal-title":"Blood"},{"key":"1868_CR169","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41577-024-01062-0","volume":"24","author":"L Akkari","year":"2024","unstructured":"Akkari L, Amit I, Bronte V, Fridlender ZG, Gabrilovich DI, Ginhoux F, et al. Defining myeloid-derived suppressor cells. Nat Rev Immunol. 2024;24:850\u20137.","journal-title":"Nat Rev Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01868-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01868-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:47:50Z","timestamp":1793335670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01868-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":169,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01868-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}